India's pharmaceutical sector is poised for growth as it navigates upcoming US tariff changes, according to a recent Equirus Securities report.
The report highlights that India's pharmaceutical market is experiencing robust domestic growth momentum as it prepares for a two-year transition period before the United States imposes tariffs on imported generic medications. These tariffs, announced by US President Donald Trump, will maintain a zero percent rate for two years starting August 1, 2026, before escalating to as much as 200% over the following two years.
In June, the Indian Pharmaceutical Market (IPM) achieved its strongest monthly performance in over two years, with a year-on-year growth rate of 16%. This momentum contributed to a 13.5% growth rate in the first quarter of FY27. The report attributes this success to improved volume growth, price increases, and new product launches, all indicating heightened demand and a robust product pipeline.
All major therapy segments demonstrated double-digit growth, particularly cardiac and anti-diabetic treatments. Notably, anti-diabetic therapies have emerged as a significant segment, driven by the increasing adoption of GLP-1 medications. The overall trend reflects a balanced expansion in the domestic market, with companies like Torrent Pharma and Zydus achieving around 20% growth in June, outperforming the market.
This positive outlook suggests that as India’s pharmaceutical industry adapts to shifting global trade dynamics, the combination of strong demand and successful product introductions will support its resilience and growth in the coming years.